Hexicon^® D (Suppositories) Instructions for Use

Marketing Authorization Holder

Nizhpharm JSC (Russia)

ATC Code

G01AX (Other antimicrobial drugs and antiseptics)

Active Substance

Chlorhexidine (Rec.INN registered by WHO)

Dosage Form

Hexicon^® D

Vaginal suppositories 8 mg: 5 or 10 pcs.

Dosage Form, Packaging, and Composition

Vaginal suppositories white or white with a yellowish tint, torpedo-shaped, marbling of the surface is allowed.

	1 supp.
Chlorhexidine digluconate	8 mg

Excipients: polyethylene oxide base (polyethylene oxide 1500, polyethylene oxide 400).

5 pcs. – contour cell packs (1) – cardboard packs.
5 pcs. – contour cell packs (2) – cardboard packs.

Clinical-Pharmacological Group

Topical antiseptic for use in gynecology

Pharmacotherapeutic Group

Antiseptic

Pharmacological Action

An antiseptic preparation for topical use.

Active against gram-positive and gram-negative bacteria – Treponema pallidum, Chlamydia spp., Ureaplasma spp., Neisseria gonorrhoeae, Gardnerella vaginalis, Bacteroides fragilis; protozoa – Trichomonas vaginalis; viruses – Herpes simplex types 1 and 2.

Hexicon does not impair the functional activity of lactobacilli.

It retains activity (although somewhat reduced) in the presence of blood and pus.

Pharmacokinetics

It is practically not absorbed from the gastrointestinal tract. After accidental ingestion of 300 mg, C_max is reached in 30 minutes and is 0.206 µg/L. It is excreted mainly with feces (90%), less than 1% is excreted with urine.

Indications

Prevention of sexually transmitted diseases (including gonorrhea, syphilis, trichomoniasis, chlamydia, ureaplasmosis, genital herpes);
Prevention of infectious and inflammatory complications in obstetrics and gynecology (before surgical treatment of gynecological diseases, before and after diathermocoagulation of the cervix, before intrauterine examinations);
Treatment of chronic exo- and endocervicitis, vaginitis (including nonspecific, mixed, trichomonas).

ICD codes

Open the list of ICD codes

ICD-10 code	Indication
A51	Early syphilis
A52	Late syphilis
A54	Gonococcal infection
A56.0	Chlamydial infections of lower genitourinary tract
A56.1	Chlamydial infections of pelvic organs and other genitourinary organs
A59	Trichomoniasis
A60	Anogenital herpesviral infection [herpes simplex]
N72	Inflammatory disease of cervix uteri (including cervicitis, endocervicitis, exocervicitis)
N76	Other inflammatory diseases of vagina and vulva
N77.1	Vaginitis, vulvitis and vulvovaginitis in infectious and parasitic diseases classified elsewhere
Z29.8	Other specified prophylactic measures

ICD-11 code	Indication
1A61.Z	Early syphilis, unspecified
1A62.Z	Late syphilis, unspecified
1A7Z	Gonococcal infection, unspecified
1A81.0	Chlamydial infection of lower genitourinary tract
1A81.1	Chlamydial infection of internal reproductive organs
1A92	Trichomoniasis
1A94.Z	Anogenital herpes simplex virus infection without further specification
1F23.10	Candidiasis of vulva and vagina
1F65	Enterobiasis
1H0Z	Unspecified infection
GA00	Vulvitis
GA02.Z	Unspecified vaginitis
GA0Z	Inflammatory diseases of female genital tract, unspecified
QC05.Z	Prophylactic measures, unspecified
1A94.0	Genital or urogenital tract infection caused by Herpes simplex virus
GA41	Ulcerative or erosive diseases of vulva
GA0Z	Inflammatory diseases of female genital tract, unspecified
XA5WW1	Cervix uteri

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

For prevention of sexually transmitted diseases, administer 1 suppository intravaginally as a single dose.

Use the suppository no later than 2 hours after unprotected sexual intercourse.

For treatment of infectious and inflammatory conditions, administer 1 suppository twice daily for 7 to 10 days.

Extend the treatment course to a maximum of 20 days if clinically necessary, as determined by a physician.

Thoroughly wash hands before and after handling the suppository.

Insert the suppository deeply into the vagina while lying on your back, with knees slightly bent.

For optimal effect, administer the suppository at bedtime to facilitate absorption and prevent leakage.

Continue treatment during menstruation; do not interrupt the course.

Concurrent use of intravaginal soaps or anionic detergents is prohibited, as they inactivate chlorhexidine.

Rinse the genital area thoroughly with water before administration to remove any soap residue.

Discontinue use and consult a physician immediately if itching or allergic reactions occur.

Adverse Reactions

Possible allergic reactions, itching, which disappear after discontinuation of the drug.

Contraindications

Hypersensitivity to the components of the drug;
Allergic reactions.

Use in Pregnancy and Lactation

The drug is not contraindicated for use during pregnancy and lactation (breastfeeding).

Special Precautions

In childhood, it is recommended to use the drug Hexicon^® D.

Overdose

Currently, no cases of overdose of Hexicon^® D have been reported.

Drug Interactions

Hexicon^® D is not compatible with detergents containing an anionic group (saponins, sodium lauryl sulfate, sodium carboxymethylcellulose) and soaps. The presence of soap can inactivate Chlorhexidine, so before using the drug, soap residues must be thoroughly washed off.

Storage Conditions

The drug should be stored out of the reach of children, in a light-protected place at a temperature not exceeding 25°C (77°F).

Shelf Life

Shelf life – 2 years.

Dispensing Status

The drug is approved for use as an over-the-counter product.

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer